Barbara S Wiggins1, Jeffrey Senfield2, Helina Kassahun3, Armando Lira3, Ransi Somaratne4. 1. Department of Pharmaceutical Sciences, Pharmacy Clinical Specialist-Cardiology, Medical University of South Carolina, Charleston, SC, USA. wiggib@musc.edu. 2. Clinical Cardiac Electrophysiologist, Novant Health Heart and Vascular Institute, 1718 East 4th Street, Suite 607, Charlotte, NC, 28204, US. 3. Clinical Research Medical Director, Amgen Inc., Thousand Oaks, CA, USA. 4. Global Development Executive Medical Director, Amgen Inc., Thousand Oaks, CA, USA.
Abstract
PURPOSE OF REVIEW: To review the efficacy, safety, pharmacology, and pharmacokinetics of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. RECENT FINDINGS: PCSK9 inhibitors are a class of lipid-lowering agents that significantly reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease and hyperlipidemia. Evolocumab is a monoclonal antibody that inhibits PCSK9 and has been evaluated in phase II and III studies as monotherapy, in combination with statins and other lipid-lowering therapies, in patients who are statin intolerant, and in patients with heterozygous and homozygous familial hypercholesterolemia. Data from these studies show that evolocumab significantly reduces LDL-C levels. Treatment with evolocumab also significantly improves levels of other lipid parameters (e.g., apolipoproteins A1 and B, lipoprotein(a), non-high-density lipoprotein cholesterol, and triglycerides). Recent results indicate that LDL-C reduction with evolocumab significantly reduces the risk of cardiovascular events and is also associated with atherosclerotic plaque regression. From a safety standpoint, rates of adverse events (AEs), serious AEs, and AEs leading to discontinuation were similar between evolocumab and controls in clinical trials, and no increase in AEs was observed when evolocumab was used in combination with statins. Patients with elevated LDL-C benefit from evolocumab treatment, suggesting that evolocumab could help meet an unmet medical need in high-risk patient populations with atherosclerotic cardiovascular disease and hyperlipidemia that are unable to reduce LDL-C levels sufficiently with statin therapy alone.
PURPOSE OF REVIEW: To review the efficacy, safety, pharmacology, and pharmacokinetics of evolocumab, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. RECENT FINDINGS:PCSK9 inhibitors are a class of lipid-lowering agents that significantly reduce low-density lipoprotein cholesterol (LDL-C) levels in patients with atherosclerotic cardiovascular disease and hyperlipidemia. Evolocumab is a monoclonal antibody that inhibits PCSK9 and has been evaluated in phase II and III studies as monotherapy, in combination with statins and other lipid-lowering therapies, in patients who are statin intolerant, and in patients with heterozygous and homozygous familial hypercholesterolemia. Data from these studies show that evolocumab significantly reduces LDL-C levels. Treatment with evolocumab also significantly improves levels of other lipid parameters (e.g., apolipoproteins A1 and B, lipoprotein(a), non-high-density lipoprotein cholesterol, and triglycerides). Recent results indicate that LDL-C reduction with evolocumab significantly reduces the risk of cardiovascular events and is also associated with atherosclerotic plaque regression. From a safety standpoint, rates of adverse events (AEs), serious AEs, and AEs leading to discontinuation were similar between evolocumab and controls in clinical trials, and no increase in AEs was observed when evolocumab was used in combination with statins. Patients with elevated LDL-C benefit from evolocumab treatment, suggesting that evolocumab could help meet an unmet medical need in high-risk patient populations with atherosclerotic cardiovascular disease and hyperlipidemia that are unable to reduce LDL-C levels sufficiently with statin therapy alone.
Authors: Robert P Giugliano; Nihar R Desai; Payal Kohli; William J Rogers; Ransi Somaratne; Fannie Huang; Thomas Liu; Satishkumar Mohanavelu; Elaine B Hoffman; Shannon T McDonald; Timothy E Abrahamsen; Scott M Wasserman; Robert Scott; Marc S Sabatine Journal: Lancet Date: 2012-11-06 Impact factor: 79.321
Authors: Naveed Sattar; David Preiss; Jennifer G Robinson; C Stephen Djedjos; Mary Elliott; Ransi Somaratne; Scott M Wasserman; Frederick J Raal Journal: Lancet Diabetes Endocrinol Date: 2016-02-08 Impact factor: 32.069
Authors: Michael J Koren; Marc S Sabatine; Robert P Giugliano; Gisle Langslet; Stephen D Wiviott; Helina Kassahun; Andrea Ruzza; Yuhui Ma; Ransi Somaratne; Frederick J Raal Journal: JAMA Cardiol Date: 2017-06-01 Impact factor: 14.676
Authors: Thomas A Lagace; David E Curtis; Rita Garuti; Markey C McNutt; Sahng Wook Park; Heidi B Prather; Norma N Anderson; Y K Ho; Robert E Hammer; Jay D Horton Journal: J Clin Invest Date: 2006-11 Impact factor: 14.808
Authors: Erin A Bohula; Robert P Giugliano; Christopher P Cannon; Jing Zhou; Sabina A Murphy; Jennifer A White; Andrew M Tershakovec; Michael A Blazing; Eugene Braunwald Journal: Circulation Date: 2015-09-01 Impact factor: 29.690
Authors: Steven E Nissen; Erik Stroes; Ricardo E Dent-Acosta; Robert S Rosenson; Sam J Lehman; Naveed Sattar; David Preiss; Eric Bruckert; Richard Ceška; Norman Lepor; Christie M Ballantyne; Ioanna Gouni-Berthold; Mary Elliott; Danielle M Brennan; Scott M Wasserman; Ransi Somaratne; Rob Scott; Evan A Stein Journal: JAMA Date: 2016-04-19 Impact factor: 56.272
Authors: Frederick J Raal; Narimon Honarpour; Dirk J Blom; G Kees Hovingh; Feng Xu; Rob Scott; Scott M Wasserman; Evan A Stein Journal: Lancet Date: 2014-10-01 Impact factor: 79.321
Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins Journal: Lancet Date: 2010-11-08 Impact factor: 79.321
Authors: Maria Mytilinaiou; Ioannis Kyrou; Mike Khan; Dimitris K Grammatopoulos; Harpal S Randeva Journal: Front Pharmacol Date: 2018-07-12 Impact factor: 5.810